Navigation Links
Longer Drug Regimen Still Best Against Breast Cancer
Date:6/2/2010

Giving meds sequentially, not concurrently, gives survival edge for those with early stage disease, study finds

WEDNESDAY, June 2 (HealthDay News) -- For patients with early stage breast cancer, taking chemotherapy drugs sequentially over six months helps improve their survival compared to taking them at the same time over a shorter three-month span, a new study found.

The new findings will probably come as a relief to doctors, most of whom already follow the sequential protocol, said Dr. Bhuvaneswari Ramaswamy, a breast oncologist with the Ohio State University Comprehensive Cancer Center--Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus.

But the "most exciting and surprising finding," said study lead author Dr. Sandra M. Swain, was that younger women who went into early menopause because of their chemotherapy -- in other words, those who stopped having periods -- were more likely to live longer.

"That's something that's not been reported," added Swain, who is medical director of the Washington Cancer Institute, Washington Hospital Center in Washington, D.C.

And this was true irrespective of whether the women's cancers were estrogen-receptor positive (meaning estrogen furthers their growth) or not.

In the study, reported in the June 3 issue of the New England Journal of Medicine, the authors tracked outcomes for almost 5,400 women with early stage breast cancer that had spread to at least one lymph node.

The patients were randomly divided into one of three treatment groups: the sequential group, which involved three drugs (doxorubicin, cyclophosphamide and docetaxel) taken in sequence over six months; or one of two "concurrent" groups, where women received either two or three of these medications concurrently for three months.

After eight years of follow-up, 83 percent of patients in the sequential group were still alive compared to 79 percent of those in the concurrent groups, the authors report.

Disease-free survival was also better in the sequential group, leading to the conclusion that a longer course of treatment remains better than a shorter course, the study said.

However, an accompanying editorial in the journal pointed out that the side effects associated with the longer program might not be worth the small survival advantage for many women.

As to the issue of amenorrhea (cessation of menstrual cycles) also improving survival, Swain said, this "really generated a new hypothesis that connects cessation of menses with survival."

No periods mean less estrogen is circulating in the body and estrogen is known to fuel certain types of cancers. But that isn't a likely explanation in this study, given that amenorrhea also resulted in longer survival even in women whose tumors were estrogen-receptor (ER) negative -- that is, their cancers don't respond to estrogen.

"This [study] gives us a hint that women who stop having their periods -- even in the patients who are not ER positive -- may have a survival advantage," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La.

However, given that so much remains unknown, the message to women is not that suppressing ovarian function is a way to reduce their risk of breast cancer, said another study author, Dr. Charles E. Geyer Jr., director of medical affairs of the National Surgical Adjuvant Breast and Bowel Project (which conducted the trial) and vice chair of human oncology at Allegheny General Hospital in Pittsburgh.

More information

To learn more about breast cancer, visit the U.S. National Cancer Institute.



SOURCES: Bhuvaneswari Ramaswamy, M.D., breast oncologist, Ohio State University Comprehensive Cancer Center--Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus; Sandra M. Swain, M.D., medical director, Washington Cancer Institute, Washington Hospital Center, Washington D.C.; Charles E. Geyer Jr., M.D., director of medical affairs, NSABP and vice chair of human oncology, Allegheny General Hospital, Pittsburgh; Jay Brooks, M.D., chairman of hematology/oncology, Ochsner Health System, Baton Rouge, La.; June 3, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Using Nicotine Patch Longer Boosts Efforts to Quit
2. Sedation Linked to Longer Stay in ICU
3. Zambian study finds longer breastfeeding best for HIV-infected mothers
4. Pet Health Insurance Grows as Pets Live Longer and Healthier Lives
5. Marijuana Use No Longer Dropping Among U.S. Teens
6. Looking Younger Than Your Age May Mean Longer Life
7. Military children face more emotional challenges as parental deployments grow longer, study finds
8. Glaucoma Drugs May Play Role in Longer Life
9. Biological clock could be a key to better health, longer life
10. Big Smiles, Longer Lives?
11. Perhaps a longer lifespan, certainly a longer health span
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... MEDIA, Pa. , June 23, 2016 ... treatments in an outpatient dialysis facility.  Treatments are usually ... to 6 hours per visit, including travel time, equipment ... on a patient, but especially grueling for patients who ... residents of a skilled nursing and rehabilitation centers for ...
(Date:6/23/2016)... 23, 2016 The Biotechnology industry ... to present great opportunities to investors. Stock-Callers.com assesses the ... Corp. (NYSE: XON ), Vertex Pharmaceuticals Inc. ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: